In our Nexus Meets series, we chat to members of our community to learn more about them and who they’d like to work with.

So hello, my name is Henry, and I’m the co-founding CEO of Microneedle Solutions. I’m a University of Leeds graduate, where I studied biotech with enterprise.

We co-founded it, Ian and I, at the University of Leeds almost three years ago now. And that’s where we first developed the product, developed a first initial prototype, filed IP, which then subsequently allowed us to get off the space here in Nexus.

We’ve been here for two years, just past our- or coming up to our two-year anniversary. We loved it here, and we’ve been here ever since. It houses our complete novel manufacturing system that we developed from the ground up, enabling us to do all of our preclinical testing as well as helping with collaborations and networking opportunities.

So at MNS, we are developing affordable self-adhesive vaccine patches.

The idea is that we’re looking to compete with needle-based administration by offering a painless, completely painless, thermally stable and self-administered alternative. Instead of getting a needle, just imagine you get a patch that you place in your arm, you press a button, and you’ll be vaccinated.

At MNS, the way that we have to develop our product is that we have to do clinical trials and get the validation that we need.

So, so far we’ve done all of our preclinical trials, which are the tests before the clinical trials.

In 2026, we’re looking at doing our first part of that clinical study with the Leeds NHS Teaching Trust, and then we’d look to do our second part of that study in 2027 to enable us to get the product to market in 2028.

We’re looking to collaborate with drug manufacturers.

So anybody, any research group or any company that’s developing a novel drug, where they can collaborate. We understand that needles are a huge market access barrier, and we believe that with our product we can alleviate those barriers and partner with you to provide your medicine in a pain-free, thermally stable format.